Revance Therapeutics's market cap is currently $381.02M. The company's EPS TTM is $-1.922; its P/E ratio is ―; Revance Therapeutics is scheduled to report earnings on March 4, 2025, and the estimated EPS forecast is $-0.26. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 234.04M	$ 132.56M	$ 77.80M	$ 15.32M	$ 413.00K
Gross Profit	$ 81.88M	$ 80.90M	$ 54.39M	$ 10.56M	$ -102.45M
Operating Income	$ -316.78M	$ -272.17M	$ -274.68M	$ -273.16M	$ -164.46M
EBITDA	$ -290.64M	$ -305.52M	$ -255.18M	$ -259.31M	$ -156.52M
Net Income	$ -323.99M	$ -356.42M	$ -286.82M	$ -282.09M	$ -156.22M
Balance Sheet
Cash & Short-Term Investments	$ 253.91M	$ 340.71M	$ 225.07M	$ 436.50M	$ 290.12M
Total Assets	$ 478.45M	$ 581.90M	$ 531.16M	$ 720.22M	$ 340.29M
Total Debt	$ 478.43M	$ 418.47M	$ 324.51M	$ 212.11M	$ 29.34M
Net Debt	$ 341.11M	$ 309.50M	$ 213.89M	$ -121.45M	$ -141.82M
Total Liabilities	$ 630.06M	$ 569.30M	$ 462.69M	$ 345.93M	$ 114.80M
Stockholders' Equity	$ -151.60M	$ 12.60M	$ 68.47M	$ 374.29M	$ 225.49M
Cash Flow
Free Cash Flow	$ -223.46M	$ -216.56M	$ -239.61M	$ -182.72M	$ -109.40M
Operating Cash Flow	$ -216.57M	$ -193.55M	$ -221.54M	$ -178.50M	$ -106.16M
Investing Cash Flow	$ 109.74M	$ -138.80M	$ -29.66M	$ 12.13M	$ -17.59M
Financing Cash Flow	$ 136.57M	$ 331.69M	$ 29.87M	$ 331.48M	$ 221.66M

Currency in USD

Revance Therapeutics Earnings and Revenue History

Income Statement >

Revance Therapeutics Debt to Assets

Balance Sheet >

Revance Therapeutics Cash Flow

Cash Flow >

Revance Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing